Ocubio Announces Appointment of Jim Mazzo and Dr. Eric Donnenfeld as Strategic AdvisorsMIAMI, April 30, 2026 (GLOBE NEWSWIRE) -- Ocubio, a biotechnology company advancing personalized, biologic-based therapies for ocular surface disease, today announced the appointment of James V. Mazzo and Eric D. Donnenfeld, MD, as Strategic Advisors.
